Onyx Pharmaceuticals (ONXX) Lower After Nexavar Lung Cancer Study Ended
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Join SI Premium – FREE
Shares of Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) are 20% lower in pre-open trading after the company and partner announced that a Phase 3 trial evaluating Nexavar tablets in patients with non-small cell lung cancer was stopped early following a planned interim analysis, when the independent Data Monitoring Committee concluded that the study would not meet its primary endpoint of improved overall survival.
The companies said safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone.
The companies said safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone.
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Holcim said to acquire part of James Hardie's EU business
- Startup Micro1 offering $12.5M for Spirit Airlines data - Business Insider
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
